Israeli company Galmed gets positive trial results for liver drug


TEL AVIV (Reuters) – Galmed Pharmaceuticals said on Tuesday patients in a mid-stage trial for its treatment for NASH, a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat.

The results will allow Galmed to meet with regulators as soon as possible and discuss a pivotal Phase 3 study design, Galmed CEO Allen Baharaff said.

The company’s shares were up 220 percent at $22.42 in premarket trade on Nasdaq.

Patients in the Phase 2b study of Galmed’s drug Aramchol had magnetic resonance spectroscopy (MRS) and biopsy at the start of the study and…



Read More Here

Be the first to comment on "Israeli company Galmed gets positive trial results for liver drug"

Leave a comment

Your email address will not be published.


*